share_log

10-Q: Q2 2024 Earnings Report

10-Q: Q2 2024 Earnings Report

10-Q:2024財年二季報
美股SEC公告 ·  2024/07/27 00:08

牛牛AI助理已提取核心訊息

Bristol-Myers Squibb reported Q2 2024 revenues of $12.2 billion, up 9% year-over-year, driven by strong performance in its Growth Portfolio and Eliquis. Net earnings were $1.68 billion with diluted EPS of $0.83. The Growth Portfolio, including Opdivo, Orencia and Yervoy, saw an 18% increase in revenue to $5.6 billion, while the Legacy Portfolio grew 2% to $6.6 billion.The company completed several strategic acquisitions in 2024, including Karuna Therapeutics, RayzeBio, and Mirati Therapeutics, strengthening its pipeline across key therapeutic areas. BMS also entered into a collaboration with SystImmune for co-development of BL-B01D1. To fund these acquisitions, the company issued $13 billion in senior unsecured notes during Q1 2024.Looking ahead, BMS continues to execute on its $1.5 billion cost savings initiative by end of 2025, focusing resources on R&D programs with the highest potential returns. The company received multiple regulatory approvals including Breyanzi for additional indications and Krazati for colorectal cancer. Operating cash flow remained strong at $5.2 billion for the first half of 2024, supporting continued investment in innovation and growth.
Bristol-Myers Squibb reported Q2 2024 revenues of $12.2 billion, up 9% year-over-year, driven by strong performance in its Growth Portfolio and Eliquis. Net earnings were $1.68 billion with diluted EPS of $0.83. The Growth Portfolio, including Opdivo, Orencia and Yervoy, saw an 18% increase in revenue to $5.6 billion, while the Legacy Portfolio grew 2% to $6.6 billion.The company completed several strategic acquisitions in 2024, including Karuna Therapeutics, RayzeBio, and Mirati Therapeutics, strengthening its pipeline across key therapeutic areas. BMS also entered into a collaboration with SystImmune for co-development of BL-B01D1. To fund these acquisitions, the company issued $13 billion in senior unsecured notes during Q1 2024.Looking ahead, BMS continues to execute on its $1.5 billion cost savings initiative by end of 2025, focusing resources on R&D programs with the highest potential returns. The company received multiple regulatory approvals including Breyanzi for additional indications and Krazati for colorectal cancer. Operating cash flow remained strong at $5.2 billion for the first half of 2024, supporting continued investment in innovation and growth.
施貴寶報告稱2024年第二季度營業收入爲122億,同比增長9%,主要受到其增長組合和Eliquis強勁表現的驅動。淨收益爲16.8億,攤薄後每股收益爲0.83美元。增長組合,包括Opdivo、Orencia和Yervoy,營業收入增加18%至56億,而傳統組合增長2%至66億。公司在2024年完成了幾項戰略收購,包括Karuna Therapeutics、RayzeBio和Mirati Therapeutics,加強了其在關鍵治療領域的產品線。施貴寶還與SystImmune達成合作,共同開發BL-B01D1。爲了資助這些收購,公司在2024年第一季度發行了130億的高級無擔保票據。展望未來,施貴寶繼續執行其到2025年底節省15億成本的計劃,集中資源於回報潛力最高的研發項目。公司獲得了多個監管批准,包括Breyanzi的額外適應症和Krazati用於結直腸癌。2024年上半年的經營現金流保持強勁,達到52億,支持持續的創新與增長投資。
施貴寶報告稱2024年第二季度營業收入爲122億,同比增長9%,主要受到其增長組合和Eliquis強勁表現的驅動。淨收益爲16.8億,攤薄後每股收益爲0.83美元。增長組合,包括Opdivo、Orencia和Yervoy,營業收入增加18%至56億,而傳統組合增長2%至66億。公司在2024年完成了幾項戰略收購,包括Karuna Therapeutics、RayzeBio和Mirati Therapeutics,加強了其在關鍵治療領域的產品線。施貴寶還與SystImmune達成合作,共同開發BL-B01D1。爲了資助這些收購,公司在2024年第一季度發行了130億的高級無擔保票據。展望未來,施貴寶繼續執行其到2025年底節省15億成本的計劃,集中資源於回報潛力最高的研發項目。公司獲得了多個監管批准,包括Breyanzi的額外適應症和Krazati用於結直腸癌。2024年上半年的經營現金流保持強勁,達到52億,支持持續的創新與增長投資。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。